What is Kisspeptin-10?
Kisspeptin-10 is the shortest active fragment of kisspeptin, the peptide from the hypothalamus (the brain's hormone control center) that drives release of GnRH, the master switch for reproductive hormones. Small randomized studies against placebo or vehicle show it raises LH (with FSH, one of the pituitary hormones that drive the testes and ovaries) in healthy men, healthy women, and women with polycystic ovary syndrome, and a 2026 study in healthy men sustained increases in LH, FSH, and testosterone for 12 days with daily infusions, but no trial has tested a clinical outcome with kisspeptin-10 itself; the randomized trial in men with low sexual desire used the longer kisspeptin-54. FDA placed kisspeptin-10 on the 503A Category 2 list (compounding ingredients flagged for significant safety risks) in September 2023 and it remains there as of April 2026, so a 503A pharmacy has no federal basis to compound it from bulk, and it is prohibited in sport under WADA.
Kisspeptin-10 is a ten amino acid C-terminal fragment of kisspeptin (KISS1 gene product), an agonist at the kisspeptin receptor (KISS1R, formerly GPR54). It is also known as KP-10, Metastin (45-54), Kisspeptin 10, KISS1 decapeptide, Kisspeptin, Kisspeptin peptide, Kisspeptin-10 peptide.
How does it work?
Kisspeptin binds KISS1R on hypothalamic GnRH neurons and triggers pulsatile GnRH release, which in turn stimulates pituitary LH and FSH and downstream testosterone or estradiol. Kisspeptin-10 has the same receptor activity as full length kisspeptin-54 but a much shorter circulating half-life (minutes). Continuous exposure can desensitize the response, which is why chronic protocols use intermittent infusion. Kisspeptin also acts in limbic brain regions involved in sexual and emotional processing, the basis for its study in low sexual desire.
| Cluster | Sexual health and reproductive |
|---|---|
| Routes | Intravenous bolus or infusion (research studies); Subcutaneous bolus or pump infusion (research studies); Subcutaneous injection vials (unapproved drugs when sold for human use) |
| Conditions studied | Sexual dysfunction; Male hypogonadism (low testosterone); Erectile dysfunction |
| Record | v5, reviewed, verified Sep 30, 2026 |
Kisspeptin benefits: what the evidence shows
Kisspeptin-10 has been tested in small randomized studies from two academic groups in the United Kingdom, and all of them measured hormone responses rather than clinical outcomes. In two crossover studies against a vehicle infusion, intravenous kisspeptin-10 raised LH in healthy women given estradiol (20 women, half of them pretreated with a neurokinin 3 receptor blocker) and in 15 women with polycystic ovary syndrome. A 2026 randomized, single-blind, placebo-controlled study in 15 healthy men plus 12 controls found that daily 8 hour subcutaneous infusions sustained LH, FSH, and testosterone increases for 12 days without receptor desensitization. No study has tested kisspeptin-10 for a clinical outcome such as fertility, hypogonadism, or sexual function; the randomized trial in men with low sexual desire used kisspeptin-54, a different molecule.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 4 | 94 |
| Human observational studies | 2 | n/a |
| Animal studies | 0 | n/a |
| All indexed studies | 6 | 94 |
Human evidence
Jayasena 2011: intravenous bolus kisspeptin-10 increased serum LH and FSH in healthy men at 0.3 and 1.0 nmol/kg; in women no gonadotropin response occurred in the follicular phase at any dose or route, while LH and FSH rose in the preovulatory phase (n = 4 to 5 per group). Jayasena 2015: direct comparison of intravenous kisspeptin-10, kisspeptin-54, and GnRH in healthy men. Skorupskaite 2016: healthy women given estradiol, 10 pretreated with a neurokinin 3 receptor blocker and 10 untreated, were randomized to an intravenous kisspeptin-10 or vehicle infusion with the alternate infusion in a later cycle; kisspeptin-10 raised LH, and LH stayed elevated after the infusion stopped. Skorupskaite 2020: 15 women with polycystic ovary syndrome (8 pretreated with a neurokinin 3 receptor blocker, 7 untreated) were randomized to kisspeptin-10 or vehicle in the same crossover design; kisspeptin-10 raised LH with and without the blocker. Yeung 2026: in a randomized, single-blind, placebo-controlled study of 15 healthy men and 12 controls, acute subcutaneous kisspeptin-10 infusions dose-dependently raised LH, FSH, and testosterone; continuous 5 day infusion at 180 nmol/h did not sustain gonadotropins, but daily 8 hour infusions at 150 nmol/h for 12 days did, and the receptor remained responsive afterward. The randomized trial of sexual function (Mills 2023, 32 men with hypoactive sexual desire disorder) used intravenous kisspeptin-54, not kisspeptin-10, and found increased sexual brain activation and penile tumescence.
Animal evidence
Kisspeptin-10 stimulates gonadotropin release in male and female rodents, sheep, and non-human primates through KISS1R on GnRH neurons; knockout of the receptor causes hypogonadotropic hypogonadism in mice and humans. Chronic continuous exposure in animals produces desensitization and suppression of the reproductive axis.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans2011 PMID 21976724 | Physiology study of intravenous and subcutaneous kisspeptin-10 versus vehicleHealthy men and women (n = 4 to 5 per group) | LH and FSH rose in men at 0.3 to 1.0 nmol/kg intravenous bolus; no response in women in the follicular phase; response in the preovulatory phase | Evidence: Human observational evidence |
| Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men2015 PMID 26089302 | Crossover physiology studyHealthy men | All three peptides stimulated LH and FSH; profiles of response differed by peptide | Evidence: Human observational evidence |
| Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men2026 PMID 42549827 | Randomized, single-blind, placebo-controlled physiology study in three partsn = 27 15 healthy men receiving kisspeptin-10 and 12 controls | Acute infusions dose-dependently raised LH, FSH, and testosterone; daily 8 hour infusions at 150 nmol/h sustained increases for 12 days; continuous infusion did not sustain gonadotropins | Evidence: Human RCT evidence |
| Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial2023 PMID 36735255 | Double-blind, placebo-controlled, two-way crossover randomized trial of intravenous kisspeptin-54 (not kisspeptin-10)n = 32 Heterosexual men with hypoactive sexual desire disorder | Kisspeptin-54 modulated sexual processing brain activity (Cohen d 0.81) and increased penile tumescence by up to 56% more than placebo | Evidence: Human RCT evidence |
| Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women2016 PMID 27636018 | Randomized, vehicle-controlled, two-way crossover study of intravenous kisspeptin-10 infusion during estradiol treatmentn = 20 Healthy women with regular menses given transdermal estradiol: 10 pretreated with a neurokinin 3 receptor antagonist and 10 untreated controls | Hormone endpoints: kisspeptin-10 increased LH secretion during the inhibitory phase of estradiol feedback, and LH remained elevated after the infusion ended; with the antagonist the LH rise was not significant and FSH rose | Evidence: Human RCT evidence |
| Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome2020 PMID 32510130 | Randomized, vehicle-controlled crossover study of intravenous kisspeptin-10 infusionn = 15 Women with polycystic ovary syndrome: 8 pretreated with a neurokinin 3 receptor antagonist for 7 days and 7 untreated | Hormone endpoints: kisspeptin-10 increased LH secretion without the antagonist (5.2 to 7.8 IU/L) and after it (9.0 versus 3.5 IU/L with vehicle) | Evidence: Human RCT evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Sexual dysfunction | Evidence: Human observational evidence | Small human studies of kisspeptin-10 measured reproductive hormone release, not sexual function; no trial has tested kisspeptin-10 for sexual function, and the randomized trial of sexual brain processing in men with low sexual desire used kisspeptin-54, a different molecule; not approved. |
| Male hypogonadism (low testosterone) | Evidence: Human observational evidence | In a randomized, single-blind, placebo-controlled physiology study (15 healthy men plus 12 controls), daily infusions raised LH, FSH, and testosterone for 12 days; hormone endpoints in healthy men only, and no trial has tested kisspeptin-10 in men with hypogonadism; experimental and not approved. |
| Erectile dysfunction | Evidence: Human observational evidence | The randomized trial that found increased penile tumescence and sexual brain processing in men with low sexual desire used kisspeptin-54, a different molecule; no trial has tested kisspeptin-10 for erectile function, and its human studies measured hormone responses only; experimental. |
Is Kisspeptin-10 legal in the United States?
FDA and compounding status
FDA placed kisspeptin-10 on the 503A Category 2 list (substances that may present significant safety risks) on September 29, 2023, citing immunogenicity risk, peptide impurities, and no or limited safety information. As of the FDA page current to April 22, 2026, kisspeptin-10 remains in Category 2 and was not among the peptides withdrawn in April 2026 or taken up by the Pharmacy Compounding Advisory Committee in July 2026. It is not an FDA approved drug and a 503A pharmacy may not compound it.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- WADA
WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times
The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.
- FDA
FDA places a batch of nominated peptides in 503A Category 2
In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.
Full tracker for Kisspeptin-10 or the category-wide tracker.
Email me when Kisspeptin-10's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of Kisspeptin-10 used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Human physiology studies used intravenous bolus doses of 0.3 to 10 nmol/kg, subcutaneous bolus up to 32 nmol/kg, and intravenous infusion up to 720 pmol/kg/min (Jayasena 2011); subcutaneous infusions of 150 to 180 nmol/h for 8 hours daily or continuously (Yeung 2026). These were research protocols in healthy volunteers, not treatment regimens.
Routes reported
| # | Route |
|---|---|
| 1 | Intravenous bolus or infusion (research studies) |
| 2 | Subcutaneous bolus or pump infusion (research studies) |
| 3 | Subcutaneous injection vials (unapproved drugs when sold for human use) |
Kisspeptin side effects
Side effects
| # | Reported side effect |
|---|---|
| 1 | No adverse effects reported in short research protocols in healthy volunteers |
| 2 | Continuous exposure can suppress gonadotropin release (desensitization) |
| 3 | No long-term human safety data |
| 4 | FDA cites limited safety information and immunogenicity concerns for compounded product |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal interaction studies exist |
| 2 | Theoretical interaction with GnRH agonists and antagonists, testosterone, and other agents acting on the hypothalamic pituitary gonadal axis |
Contraindications
| # | Contraindication |
|---|---|
| 1 | No approved indication; not for use outside research |
| 2 | Pregnancy (kisspeptin is elevated in pregnancy but exogenous dosing has not been studied) |
| 3 | Hormone sensitive cancers (theoretical, via sex steroid stimulation) |
| 4 | Competitive athletes subject to WADA testing |
How do people access Kisspeptin-10 legally?
Typical cost: Not available through licensed channels. Research chemical sellers list it, but those products are unapproved drugs when sold for human use and are not verified for purity.
Access options
Not available
Not legally available for human use in the United States outside a clinical trial.
Not available
Not an FDA approved drug; on the FDA 503A Category 2 list.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare Kisspeptin-10
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. PeptideAgent has not found an FDA warning letter or review that names Kisspeptin-10. [11] [12] [13]
Being offered does not change the legal status of Kisspeptin-10. Kisspeptin-10 is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [5] [14]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [5] [6] [11] [15] [16] [17]
What that means for you
- A pharmacy that compounds Kisspeptin-10 is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [11] [15]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [6]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [18]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [19] [20]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [5]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, Kisspeptin-10 is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [7]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound Kisspeptin-10, with or without a prescription. [14]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [21] [22] [23]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [13] [23] [24]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [6] [25] [26] [27] [28] [29]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [6]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [21]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [13]
- Pharmacy: Is this made for me on a prescription written in my name? [24]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [13] [23]
- Prescriber: What is the legal basis for a pharmacy to compound Kisspeptin-10? Is it FDA approved or on the 503A bulks list? [6] [14]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [13]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [18]
Frequently asked questions
What is kisspeptin?
Kisspeptin is a natural hormone made in the hypothalamus, the brain's hormone control center, that switches on GnRH release, which in turn drives LH, FSH (the pituitary signals to the testes and ovaries), and sex hormone production. Kisspeptin-10 is its shortest active fragment and kisspeptin-54 is the longer circulating form; both are used in research studies. Neither is FDA approved, and kisspeptin-10 is on the FDA 503A Category 2 list (compounding ingredients flagged for significant safety risks), so a 503A pharmacy has no federal basis to compound it from bulk. [1] [2] [5]
Is kisspeptin-10 legal in the United States?
No FDA approved or lawfully compounded source exists for human use. Kisspeptin-10 is not an approved drug, and FDA placed it on the 503A Category 2 list in September 2023, which means compounding pharmacies may not use it. As of April 2026 it is still in Category 2. Products sold as research chemicals for human use are unapproved drugs. [5] [6] [10]
Does kisspeptin-10 increase testosterone?
In healthy men, yes, at least in the short term. Intravenous bolus doses raised LH and FSH within hours, and a 2026 study of 15 healthy men found daily 8 hour subcutaneous infusions sustained increases in LH, FSH, and testosterone for 12 days. Whether that translates to any clinical benefit in men with low testosterone has not been tested, and continuous exposure suppressed the response. [1] [3]
Does kisspeptin work for low libido?
The randomized trial that made headlines used kisspeptin-54, not kisspeptin-10. In 32 men with hypoactive sexual desire disorder, a 75 minute intravenous kisspeptin-54 infusion increased activation of sexual processing brain regions and penile tumescence compared with placebo. That was a single dose mechanistic study, not a treatment trial, and no study has tested kisspeptin-10 for sexual desire. [4]
What are the side effects of kisspeptin-10?
In short research protocols in healthy volunteers no adverse effects were reported, but those studies were tiny and lasted hours to days. There are no long-term safety data. FDA lists immunogenicity risk and peptide impurities as concerns for compounded product, and continuous exposure can suppress rather than stimulate reproductive hormones. [3] [5]
How is kisspeptin-10 taken?
Only by intravenous or subcutaneous infusion or bolus in research settings. Because its half-life is minutes, studies that wanted a sustained effect used pump infusions for 8 hours a day. There is no established treatment dose or schedule, and injection vials sold online have not been studied. [1] [3]
How much does kisspeptin-10 cost?
There is no licensed price because it is not FDA approved and is on FDA's 503A Category 2 list, so a 503A pharmacy has no federal basis to compound it. Research chemical listings exist but those products are unapproved drugs when sold for human use and are not tested for purity, so PeptideAgent does not report them as a cost of treatment. [5] [10]
Is kisspeptin-10 banned by WADA?
Yes. Kisspeptin and its agonist analogues are named in section S2.2.1 of the WADA Prohibited List, which applies at all times and to male athletes only. [7]
Kisspeptin-10 vs gonadorelin: which is better for keeping testosterone up on TRT?
Neither has a trial for that use. Gonadorelin is GnRH itself, which works only when delivered in pulses by a pump; kisspeptin-10 acts one step upstream and also needs intermittent dosing. Gonadorelin was the active ingredient of approved products and can be compounded; kisspeptin-10 is on the FDA Category 2 list and cannot. Both are prohibited for male athletes under WADA. [3] [5] [7]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Peptides for men, ranked by human evidence
hCG, GLP-1 drugs, teriparatide, and tesamorelin have human trials and a lawful route. PT-141 is off-label in men; kisspeptin and melanotan II have no approval or 503A listing. Ranking, legality, WADA.
- Peptides for women, ranked by human evidence
GLP-1 drugs, teriparatide, abaloparatide, and Vyleesi (PT-141) have real trials in women. Kisspeptin is research-only and GHK-Cu rests on small skin studies. The ranking and legal status.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Jayasena CN et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab 2011PubMed 21976724, 2011
- [2]Jayasena CN et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod 2015PubMed 26089302, 2015
- [3]Yeung AC et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol 2026PubMed 42549827, 2026
- [4]Mills EG et al. Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open 2023PubMed 36735255, 2023
- [5]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
- [6]FDA: Compounding and the FDA, questions and answersFDA, 2026
- [7]WADA Prohibited List, sections S0 and S2WADA, 2026
- [8]Skorupskaite K et al. Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women. J Clin Endocrinol Metab 2016PubMed 27636018, 2016
- [9]Skorupskaite K et al. Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome. Hum Reprod 2020PubMed 32510130, 2020
- [10]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 30). Kisspeptin-10: evidence, legality, and access. https://peptideagent.ai/peptides/kisspeptin-10- HTML link
<a href="https://peptideagent.ai/peptides/kisspeptin-10">Kisspeptin-10: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.